ALNYLAM PHARMACEUTICALS, INC. Income (Loss) from Equity Method Investments
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Income (Loss) from Equity Method Investments of -$4.52 million for the 12-month period ending 2012-12-31, per its 10-K filed 2015-02-13.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2015-02-13
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from equity method investments for the quarter ending 2012-12-31 was -$881.00K.
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from equity method investments for the quarter ending 2012-09-30 was -$1.61M.
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from equity method investments for the quarter ending 2012-06-30 was -$1.14M.
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from equity method investments for the quarter ending 2012-03-31 was -$889.00K.
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from equity method investments for fiscal 2012 was -$4.52M.
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from equity method investments for fiscal 2011 was -$3.50M.
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from equity method investments for fiscal 2010 was -$7.64M.
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from equity method investments for fiscal 2009 was -$4.91M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2012-12-31 | -$881.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | -$2.49M derived: sum of 2 quarters · filed 2015-02-13 | -$3.63M derived: sum of 3 quarters · filed 2015-02-13 | -$4.52M 10-K · filed 2015-02-13 |
| 2012-09-30 | -$1.61M 10-Q · filed 2013-11-07 | -$2.75M derived: sum of 2 quarters · filed 2013-11-07 | -$3.64M 10-Q · filed 2013-11-07 | -$4.59M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | -$1.14M 10-Q · filed 2013-08-09 | -$2.03M 10-Q · filed 2013-08-09 | -$2.98M derived: sum of 3 quarters · filed 2014-02-20 | -$3.45M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-03-31 | -$889.00K 10-Q · filed 2013-05-07 | -$1.84M derived: sum of 2 quarters · filed 2014-02-20 | -$2.31M derived: sum of 3 quarters · filed 2014-02-20 | -$3.32M derived: sum of 4 quarters · filed 2014-02-20 |
| 2011-12-31 | -$954.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | -$1.42M derived: sum of 2 quarters · filed 2014-02-20 | -$2.43M derived: sum of 3 quarters · filed 2014-02-20 | -$3.50M 10-K · filed 2014-02-20 |
| 2011-09-30 | -$467.00K 10-Q · filed 2012-11-05 | -$1.48M derived: sum of 2 quarters · filed 2012-11-05 | -$2.55M 10-Q · filed 2012-11-05 | -$3.47M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-06-30 | -$1.01M 10-Q · filed 2012-08-08 | -$2.08M 10-Q · filed 2012-08-08 | -$3.00M derived: sum of 3 quarters · filed 2013-02-19 | -$4.23M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-03-31 | -$1.07M 10-Q · filed 2012-05-03 | -$1.99M derived: sum of 2 quarters · filed 2013-02-19 | -$3.21M derived: sum of 3 quarters · filed 2013-02-19 | -$7.13M derived: sum of 4 quarters · filed 2013-02-19 |
| 2010-12-31 | -$916.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | -$2.14M derived: sum of 2 quarters · filed 2013-02-19 | -$6.06M derived: sum of 3 quarters · filed 2013-02-19 | -$7.64M 10-K · filed 2013-02-19 |
| 2010-09-30 | -$1.23M 10-Q · filed 2011-11-03 | -$5.14M derived: sum of 2 quarters · filed 2011-11-03 | -$6.72M 10-Q · filed 2011-11-03 | -$8.21M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-06-30 | -$3.92M 10-Q · filed 2011-08-03 | -$5.50M 10-Q · filed 2011-08-03 | -$6.99M derived: sum of 3 quarters · filed 2012-02-13 | -$8.12M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-03-31 | -$1.58M 10-Q · filed 2011-05-05 | -$3.07M derived: sum of 2 quarters · filed 2012-02-13 | -$4.20M derived: sum of 3 quarters · filed 2012-02-13 | -$5.02M derived: sum of 4 quarters · filed 2012-02-13 |
| 2009-12-31 | -$1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-13 | -$2.62M derived: sum of 2 quarters · filed 2012-02-13 | -$3.44M derived: sum of 3 quarters · filed 2012-02-13 | -$4.91M 10-K · filed 2012-02-13 |
| 2009-09-30 | -$1.14M 10-Q · filed 2010-11-04 | -$1.95M derived: sum of 2 quarters · filed 2010-11-04 | -$3.42M 10-Q · filed 2010-11-04 | |
| 2009-06-30 | -$816.00K 10-Q · filed 2010-08-05 | -$2.29M 10-Q · filed 2010-08-05 | ||
| 2008-12-31 | -$9.29M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |